Journal of Antimicrobial Chemotherapy · 2012 · 30 citations · 30 references
Life SciencesEntomologyMicrobiologyAntimicrobial PharmacologyAntimicrobial PharmacotherapyInsect ImmunologyAntibacterial AgentsInsect Immune ResponsesInsect PathogensPathogenesis In InsectsBiting FliesDrosophila Disease ModelsDrosophila ModelsIn Vivo Efficacy TestingIn Vivo StudiesInsect Immune Response To PathogensModel-based Drug Efficacy AnalysisMycobacterium Tuberculosis Infection
OBJECTIVES: The major advantages of Drosophila melanogaster are a well-characterized immune system and high degree of susceptibility to tuberculosis caused by Mycobacterium marinum. The D. melanogaster-M. marinum infection model is gaining momentum as a screening tool because it is genetically amenable, low priced, rapid, technically convenient and ethically acceptable. In this context, the aim of this study was to develop a new, effective D. melanogaster-M. marinum in vivo efficacy model for antimycobacterial drug discovery. METHODS: D. melanogaster were challenged with intra-abdominal injections of M. marinum and infected flies were fed with a fly medium containing isoniazid, rifampicin, ethambutol, pyrazinamide, amikacin, dinitrobenzamide or ampicillin dissolved in DMSO at different concentrations (0, 100 and 500 mg/L). Bacterial dissemination in flies was monitored by fluorescence microscopy/cfu counts and a fly survival curve was plotted. RESULTS: The D. melanogaster-M. marinum model allowed assessment of the effectiveness of antibiotic treatment not only with conventional drugs, but also with newly discovered antimycobacterial agents. Rifampicin, dinitrobenzamide, amikacin and isoniazid effectively extended the life span of infected flies and ethambutol showed slightly improved survival. However, M. marinum infection was not cured by ampicillin or pyrazinamide. CONCLUSIONS: This D. melanogaster-M. marinum infection/curing methodology may be valuable in the rapid evaluation of the activity of new antimycobacterial agents in drug discovery.
30
L A Collins, Scott G. Franzblau · Antimicrobial Agents and Chemotherapy · 1997 · 1.6K citations · Full text
Veterinary Medicine, Infectious Diseases, Antimicrobial Pharmacology +7
Susan Broughton, Matthew D. W. Piper, Tomoatsu Ikeya et al. · Proceedings of the National Academy of Sciences · 2005 · 840 citations · Full text
Pyrazinamide Inhibits Trans-Translation in <i>Mycobacterium tuberculosis</i>
Wanliang Shi, Xuelian Zhang, Xin Jiang et al. · Science · 2011 · 510 citations · Full text